Ticker >

Ajanta Pharma share price

Ajanta Pharma Ltd.

NSE: AJANTPHARM BSE: 532331 SECTOR: Pharmaceuticals & Drugs  82k   492   49

2240.00
+56.70 (2.60%)
BSE: 28 Mar 04:01 PM

Price Summary

Today's High

₹ 2240

Today's Low

₹ 2181.6

52 Week High

₹ 2355.05

52 Week Low

₹ 1191.35

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

28205.11 Cr.

Enterprise Value

27935.19 Cr.

No. of Shares

12.59 Cr.

P/E

37.03

P/B

7.89

Face Value

₹ 2

Div. Yield

0.31 %

Book Value (TTM)

₹  283.99

CASH

269.92 Cr.

DEBT

0 Cr.

Promoter Holding

66.21 %

EPS (TTM)

₹  60.5

Sales Growth

8.62%

ROE

17.42 %

ROCE

21.98%

Profit Growth

-22.38 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Ajanta Pharma Ltd.

Met XL Softdrops Sunstop Kamagra Melacare Cinod Feburic Forticord Zaha Ilapro

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.62%
3 Year15.81%
5 Year13.32%

Profit Growth

1 Year-22.38%
3 Year8.2%
5 Year5.5%

ROE%

1 Year17.42%
3 Year22.16%
5 Year20.98%

ROCE %

1 Year21.98%
3 Year28.68%
5 Year27.65%

Debt/Equity

0

Price to Cash Flow

38.31

Interest Cover Ratio

134.814531548757

CFO/PAT (5 Yr. Avg.)

0.84615246617464

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 66.21 12.33
Sep 2023 66.21 12.43
Jun 2023 66.21 13.23
Mar 2023 66.11 11.41
Dec 2022 66.11 19.87
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 15.8064986380471% for the Past 3 years.
  • Company has been maintaining healthy ROE of 22.1617427954213% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.678463800126% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 134.814531548757.
  • The Company has been maintaining an effective average operating margins of 26.5561217562662% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 36.8367648151601 days.
  • Company has a healthy liquidity position with current ratio of 2.8014517976736.

 Limitations

  • The company has shown a poor profit growth of 8.19550241248637% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 874.89 848.86 1014.58 945.18 1085.29
Total Expenditure 715.48 704.33 737.68 671.53 758.11
Operating Profit 159.41 144.53 276.9 273.65 327.18
Other Income 30.51 36.75 31.46 52.16 13.73
Interest 2.68 1.21 0.75 2.27 2.36
Depreciation 32.29 32.11 32.24 33.04 33.41
Exceptional Items 0 0 0 0 0
Profit Before Tax 154.95 147.96 275.37 290.5 305.14
Tax 30.99 30.75 63.33 78.14 84.99
Profit After Tax 123.96 117.21 212.04 212.36 220.15
Adjusted EPS (Rs) 9.64 9.28 16.78 16.81 17.42

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 1772.62 2196.42 2718.59 3140.64 3411.27
Total Expenditure 1291.41 1663.64 1801.68 2249.75 2711.99
Operating Profit 481.21 532.78 916.91 890.89 699.28
Other Income 102.15 184.2 103.57 139.73 132.75
Interest 0.41 9.1 6.9 9.12 5.23
Depreciation 69.9 91.29 111.49 120.96 126.95
Exceptional Items 0 -3.92 0 0 0
Profit Before Tax 513.05 612.67 902.09 900.54 699.85
Tax 121.29 171.54 226.45 180.68 141.13
Net Profit 391.76 441.13 675.64 719.86 558.72
Adjusted EPS (Rs.) 29.93 33.71 52.07 56.2 44.38

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 17.54 17.54 17.39 17.17 25.27
Total Reserves 2124.54 2443.76 2867.59 3152.01 3221.18
Borrowings 0 0 0 0 0
Other N/C liabilities 193.38 252.27 321.18 338.33 272.9
Current liabilities 427.47 614.3 706.28 469.7 907.84
Total Liabilities 2762.93 3327.87 3912.44 3977.21 4427.19
Assets
Net Block 1152.14 1439.93 1509.89 1483.91 1484.01
Capital WIP 261.29 131.06 108.19 152.86 209.47
Intangible WIP 0 0 0 0 0
Investments 18.26 18.63 17.89 42.99 42.99
Loans & Advances 148.1 165.33 230.52 226.15 134.68
Other N/C Assets 13.97 18.48 19.55 14.29 12.77
Current Assets 1169.17 1554.44 2026.4 2057.01 2543.27
Total Assets 2762.93 3327.87 3912.44 3977.21 4427.19
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 513.05 612.67 902.09 900.54 699.85
Adjustment -11.56 -36.6 37.07 55.58 79.34
Changes in Assets & Liabilities -86.64 -136.66 -274.26 -220.31 82.66
Tax Paid -103.03 -138.53 -197.91 -193.47 -125.56
Operating Cash Flow 311.82 300.88 466.99 542.34 736.29
Investing Cash Flow -136.88 -115.91 -162.68 -66.04 -501.31
Financing Cash Flow -180.89 -134 -268.9 -457.3 -105.12
Net Cash Flow -5.95 50.97 35.41 19 129.86

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 66.11 66.11 66.21 66.21 66.21
aayush m agrawal 0.02 0.02 - 0.02 0.02
aayush m agrawal, trustee... 11.33 11.33 11.31 11.31 11.31
gabs investments pvt ltd 9.83 9.83 10.00 10.00 10.00
ganga exports being repre... 2.69 2.69 2.68 2.68 2.68
rajesh m agrawal, trustee... 14.49 14.49 14.48 14.48 14.48
ravi p agrawal 0.22 0.22 0.23 0.23 0.23
ravi p agrawal, trustee r... 13.03 13.03 13.01 13.01 13.01
yogesh m agrawal, trustee... 14.49 14.49 14.48 14.48 14.48
aayush madhusudan agrawal... - - 0.02 - -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 33.89 33.89 33.79 33.79 33.79
invesco india contra fund... - 1.00 - - 1.03
investor education and pr... 0.08 - - - 0.09
kotak small cap fund - - - - 1.23
llp - 0.05 0.05 0.05 0.04
nippon life india trustee... - 3.21 3.16 3.16 3.12
tata aia life insurance c... - 1.21 1.51 1.64 1.64
uti flexi cap fund 4.63 4.60 4.38 3.66 3.16
investor education and pr... - 0.08 0.09 0.09 -
mirae asset large cap fun... 1.80 1.58 - - -
icici prudential value di... 1.16 - - - -
invesco india dynamic equ... 1.05 - - - -
nippon life india trustee... 2.52 - - - -
tata aia life insurance c... 1.17 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Ajanta Pharma - Quaterly Results31 Jan 2024, 4:12PM Ajanta Pharma - Quaterly Results31 Jan 2024, 4:12PM Ajanta Pharma - Quaterly Results31 Jan 2024, 4:12PM Ajanta Pharma submits intimation of record date 25 Jan 2024, 12:53PM Ajanta Pharma informs about update on board meeting 25 Jan 2024, 10:58AM Ajanta Pharma informs about loss of share certificate19 Dec 2023, 1:39PM Ajanta Pharma informs about loss of share certificate15 Dec 2023, 2:12PM Ajanta Pharma informs about disclosure 15 Dec 2023, 12:22PM Ajanta Pharma informs about revised disclosure15 Dec 2023, 12:14PM Ajanta Pharma informs about disclosures24 Nov 2023, 5:05PM Ajanta Pharma informs about loss of share certificate22 Nov 2023, 10:43AM Ajanta Pharma - Quaterly Results31 Oct 2023, 2:15PM Ajanta Pharma - Quaterly Results31 Oct 2023, 2:15PM Ajanta Pharma - Quaterly Results31 Oct 2023, 2:15PM Ajanta Pharma informs about board meeting19 Oct 2023, 3:17PM Ajanta Pharma informs about loss of share certificate27 Sep 2023, 11:32AM Ajanta Pharma informs about newspaper publication 4 Sep 2023, 11:06AM Ajanta Pharma gets USFDA’s final nod for Topiramate Extended-Release Capsules30 Aug 2023, 6:15PM Ajanta Pharma informs about investor meetings17 Aug 2023, 10:12AM Ajanta Pharma informs about details of loss of certificate 7 Aug 2023, 4:20PM Ajanta Pharma informs about outcome of board meeting27 Jul 2023, 4:51PM Ajanta Pharma - Quaterly Results27 Jul 2023, 3:52PM Ajanta Pharma - Quaterly Results27 Jul 2023, 3:52PM Ajanta Pharma - Quaterly Results27 Jul 2023, 3:52PM Ajanta Pharma informs about conference call24 Jul 2023, 12:08PM Ajanta Pharma informs about board meeting24 Jul 2023, 12:04PM Ajanta Pharma informs about disclosure21 Jul 2023, 2:44PM Ajanta Pharma inks partnership with Credible Innovations11 Jul 2023, 3:12PM Ajanta Pharma to enhance presence across select geographies in Asia, Africa3 Jul 2023, 12:09PM USFDA completes inspection at Ajanta Pharma’s Dahej formulation facility26 Jun 2023, 10:05AM Ajanta Pharma informs about updates 26 Jun 2023, 9:33AM Ajanta Pharma informs about newspaper publication 19 Jun 2023, 10:40AM Ajanta Pharma informs about newspaper publication 14 Jun 2023, 12:38PM Ajanta Pharma informs about annual secretarial compliance report10 May 2023, 3:08PM Ajanta Pharma - Quaterly Results5 May 2023, 3:39PM Ajanta Pharma - Quaterly Results5 May 2023, 3:39PM Ajanta Pharma - Quaterly Results5 May 2023, 3:39PM Ajanta Pharma informs about board meeting 27 Apr 2023, 10:17AM Ajanta Pharma informs about disclosure 21 Apr 2023, 11:54AM Ajanta Pharma informs about certificate10 Apr 2023, 10:53AM Ajanta Pharma informs about compliance certificate4 Apr 2023, 2:21PM Ajanta Pharma informs about buyback of shares14 Mar 2023, 12:59PM Ajanta Pharma informs about voting results of postal ballot 10 Mar 2023, 5:06PM Ajanta Pharma informs about loss of share certificate24 Feb 2023, 2:51PM Ajanta Pharma informs about transcript of earnings call 13 Feb 2023, 10:45AM Ajanta Pharma reports 30% fall in Q3 consolidated net profit2 Feb 2023, 11:29AM Ajanta Pharma - Quaterly Results1 Feb 2023, 3:36PM Ajanta Pharma - Quaterly Results1 Feb 2023, 3:36PM Ajanta Pharma - Quaterly Results1 Feb 2023, 3:36PM Ajanta Pharma informs about disclosure27 Jan 2023, 3:09PM

Ajanta Pharma Stock Price Analysis and Quick Research Report. Is Ajanta Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ajanta Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Ajanta Pharma cash from the operating activity was Rs 736.29 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ajanta Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ajanta Pharma , the EPS growth was -21.0285238392671 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ajanta Pharma has OPM of 20.4991103020283 % which is a good sign for profitability.
     
  • ROE: Ajanta Pharma have a average ROE of 17.4196897491898 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Ajanta Pharma is Rs 2230.85. One can use valuation calculators of ticker to know if Ajanta Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Ajanta Pharma

Ajanta Pharma Ltd Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Ajanta Pharma Ltd. is a pharmaceutical major that produces a diverse range of speciality and generic formulations. The company caters to healthcare needs across various therapeutic segments such as cardiovascular, dermatology, ophthalmology, pain management, and many others. As a long-term investor, knowing the ins and outs of a company is vital before investing in it. This article will provide an in-depth analysis of Ajanta Pharma Ltd.’s stocks based on several parameters.

Ajanta Pharma Ltd Share Price

Ajanta Pharma Ltd.’s share price is a key metric that is continuously monitored by traders and investors alike. The company is a part of the 'Pharmaceuticals - Indian' industry, which has seen immense growth. Fair value analysis shows that Ajanta Pharma’s stock is fairly valued in the market compared to other companies in the industry. It is important to also look at the historical performance of the company's stock price, which can be easily accessed through Ticker's pre-built screening tool.

Ajanta Pharma Ltd Balance Sheet

A company's balance sheet shows its financial health and is a key metric for investors to consider. Ajanta Pharma's financial statements reveal a healthy balance sheet with sound financial management. We offer our premium tool, DCF Analysis, which allows investors to determine the fair value of Ajanta Pharma’s stock based on the company's balance sheet.

Ajanta Pharma Ltd Annual Report

Investors can gain a deep understanding of Ajanta Pharma’s business model, financial performance, and growth prospects by studying its annual report. Ticker provides access to downloadable annual reports, which can then be studied to gain insight into the company's future plans and growth strategy.

Ajanta Pharma Ltd Dividend

Dividend payments by a company are an important source of returns for long-term investors. Ajanta Pharma has a track record of consistently paying a dividend to its shareholders. Investors can easily track the company's dividend history through Ticker's pre-built screening tool to make informed decisions.

Ajanta Pharma Ltd Quarterly Result

A company's quarterly results reflect its performance over a short period of time. Investors can use this information to note trends in the company's financial performance. Ticker provides access to Ajanta Pharma’s quarterly results as downloadable documents. Ticker premium tool, BVPS Analysis, can also be used to analyze the company's quarterly results and gain additional insights into the company's financial performance.

Ajanta Pharma Ltd Stock Price

A company's stock price can be influenced by numerous factors such as news, changes in market trends, or investor sentiment. Through Ticker, investors have access to accurate and real-time stock prices that can help them make informed decisions about buying or selling stocks.

Ajanta Pharma Ltd Price Chart

Price charts are an essential tool for traders and investors alike to track a company's stock performance over time. Ajanta Pharma’s stock price chart allows investors to analyze the movement of the stock price, helping them make tactical investment decisions.

Ajanta Pharma Ltd News and Concall

Keeping abreast of company news is crucial for investors to stay informed of any critical developments that could impact the company's performance. Ajanta Pharma's news and concall updates can be accessed through Ticker's pre-built screening tool.

Ajanta Pharma Ltd Transcripts and Investor Presentations

Transcripts and investor presentations provided by the company offer valuable insights into the company's operations, growth strategy, and performance. Ticker offers downloadable transcripts and investor presentations, allowing investors to track the company's progress.

Ajanta Pharma Ltd Promoters

Ajanta Pharma has a strong group of promoters focused on driving the company forward and creating value for shareholders. Ticker provides detailed information about the promoters of Ajanta Pharma, to help investors gain a better understanding of the company.

Ajanta Pharma Ltd Shareholders

Understanding the company's shareholders is key to understanding how the company is being managed. Investors can gain detailed insights into Ajanta Pharma's shareholders through ticker pre-built screening tool.

Read More
X